Medisinsk ressurssenter Lundbeck Institute Campus Et medisinsk ressurssenter innen psykiatri og nevrologi. Les mer
Expert Views Dr McIntyre discusses prevention and treatment of mental health during the pandemic Professor McIntyre provides recommendations for healthcare professionals on how to best support... Content action menuShareTestTest 2Test 3
Expert Views Professor Fagiolini addresses, ‘How can healthcare providers help patients in preventing relapse now and following the pandemic?’ Professor Andrea Fagiolini, University of Siena, presents guidance for the management of patients... Content action menuShareTestTest 2Test 3
Depresjon VideoExpert Views Treatment progression for depression and depressive episodes Content action menuShareTestTest 2Test 3
Mental health Read time: 4 minsCongress highlights How are genes involved in tailoring psychiatric treatment? Psychiatrists need an understanding of genome-wide association studies (GWAS), pharmacogenomics,... Content action menuShareTestTest 2Test 3
Schizofreni VideoExpert Views Should we challenge the way we assess functioning? Content action menuShareTestTest 2Test 3
Schizofreni Video Improvement in schizophrenia: Long and short term perspectives Content action menuShareTestTest 2Test 3
Depresjon Read time: 4 minsSatellite symposium From response and remission to full functional recovery in major depressive disorder: Is patient-involvement the missing link? Depression is a common and serious illness with heterogeneous symptoms within emotional, physical... Content action menuShareTestTest 2Test 3
Schizofreni Read time: 3 minsCongress highlights Adherent to adherence – strategies in schizophrenia Adherence to antipsychotic medication helps in achieving the best possible outcomes for patients... Content action menuShareTestTest 2Test 3
Schizofreni Read time: 3 minsSatellite symposium Improving treatment outcomes in schizophrenia: Looking beyond positive symptoms for early and effective intervention Although the symptoms of schizophrenia are troublesome for almost all persons with the disease, its... Content action menuShareTestTest 2Test 3
Depresjon Read time: 3 minsCongress highlights Challenges and perspectives in the management of major depressive disorder: How can we bridge clinical predictors and biomarkers to better treatment outcomes for more patients? Although the past 50 to 60 years of antidepressant drug development focusing on monoamines has... Content action menuShareTestTest 2Test 3
Mental health Read time: 4 minsCongress highlights The Lancet Psychiatry Commission: A blueprint for protecting physical health in people with mental illness The Lancet Psychiatry Commission: A blueprint for protecting physical health in people with mental... Content action menuShareTestTest 2Test 3
Schizofreni Video What do clinical goals mean to patients with schizophrenia? Content action menuShareTestTest 2Test 3
Depresjon Read time: 4 minsSatellite symposium Patient goals and measuring outcome crucial in MDD Asking people what they most want from depression treatment, treating to target, measurement-based... Content action menuShareTestTest 2Test 3
Schizofreni Read time: 4 minsCongress highlights Can we be bothered about apathy? Approaching negative symptoms in schizophrenia There has been an increased interest in research for the negative symptoms of schizophrenia over... Content action menuShareTestTest 2Test 3
Schizofreni Read time: 5 minsSatellite symposium Are relapse prevention and functioning sufficiently prioritized in the treatment of schizophrenia? Improving adherence and reducing rates of relapse and rehospitalization are of paramount importance... Content action menuShareTestTest 2Test 3
Depresjon Read time: 3 minsCongress highlights Immune modulation in psychiatric disorders: Are we there yet? It has been argued that drug discovery for psychiatric disorders is at a near standstill. Which... Content action menuShareTestTest 2Test 3
Schizofreni Read time: 5 minsSatellite symposium Treatment outcomes in schizophrenia – what matters to patients? Schizophrenia treatment has moved from mainly addressing relapse prevention and symptom suppression... Content action menuShareTestTest 2Test 3
Depresjon Video Does good work equal good health in working patients with MDD? Content action menuShareTestTest 2Test 3
Depresjon Read time: 4 minsSatellite symposium Emotional blunting: unresolved MDD symptom or effect of treatment? Some evidence suggests that emotional blunting is a side effect of therapy, but other evidence... Content action menuShareTestTest 2Test 3
Depresjon Read time: 4 minsCongress highlights Moving towards achieving full functional recovery in depression and getting back to pre-depression lifestyle Addressing the cognitive symptoms of depression that affect attention, memory, executive function... Content action menuShareTestTest 2Test 3
Depresjon, Schizofreni Read time: 3 minsCongress highlights What is the role of inflammation in the pathophysiology of mood disorders? Evidence supporting a role for inflammation and pro-inflammatory mediators in the pathophysiology... Content action menuShareTestTest 2Test 3
Schizofreni Read time: 4 minsCongress highlights Pros and cons of persisting with antipsychotic treatment: assessing the evidence Guidelines recommend that people with first-episode psychosis should where possible be maintained... Content action menuShareTestTest 2Test 3
Schizofreni Read time: 3 minsArticle Future of schizophrenia treatment: Where do we go now? Over the next decade, the outcomes for patients with schizophrenia should improve considerably,... Content action menuShareTestTest 2Test 3
Depresjon, Schizofreni Read time: 4 minsCongress highlights The promise of big data analysis – precision psychiatry and therapeutic targeting Psychiatric diagnosis - according to DSM-5 - is largely based on psychiatric symptoms, with a great... Content action menuShareTestTest 2Test 3
Schizofreni Read time: 2 minsCongress highlights The pros and cons of plasticity Content action menuShareTestTest 2Test 3
Schizofreni Read time: 5 minsCongress highlights Recovery – from schizophrenia symptoms to well-being Recovery in an important focus in the treatment and management of schizophrenia but what exactly is... Content action menuShareTestTest 2Test 3
Schizofreni Read time: 3 minsCongress highlights A public invitation to view and comment on pre-final APA schizophrenia guideline statements Many guidelines exist worldwide on how best to manage psychiatric illnesses, but we never see two... Content action menuShareTestTest 2Test 3
Depresjon, Schizofreni Read time: 6 minsArticle ICD-11 – fielding for diagnostic success In 2018, the World Health Organization (WHO) will release two important documents, both of which... Content action menuShareTestTest 2Test 3
Depresjon Read time: 6 minsArticle Espen Molden om bedre behandlingseffekt med psykofarmakologiske gentester Content action menuShareTestTest 2Test 3
Depresjon Read time: 6 minsArticle Haakon Aars om depresjon og seksuell helse Content action menuShareTestTest 2Test 3
Depresjon Read time: 6 minsArticle Jon Johnsen om depresjon og overvekt Content action menuShareTestTest 2Test 3
